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Manufacturing and in vivo inner ear visualization
of MRI traceable liposome nanoparticles
encapsulating gadolinium
Jing Zou1*, Rohit Sood2, Sanjeev Ranjan2†, Dennis Poe1†, Usama A Ramadan3, Paavo KJ Kinnunen2, Ilmari Pyykkö1
Abstract
Background: Treatment of inner ear diseases remains a problem because of limited passage through the blood-
inner ear barriers and lack of control with the delivery of treatment agents by intravenous or oral administration.
As a minimally-invasive approach, intratympanic delivery of multifunctional nanoparticles (MFNPs) carrying genes or
drugs to the inner ear is a future therapy for treating inner ear diseases, including sensorineural hearing loss (SNHL)
and Meniere’s disease. In an attempt to track the dynamics and distribution of nanoparticles in vivo, here we
describe manufacturing MRI traceable liposome nanoparticles by encapsulating gadolinium-tetra-azacyclo-
dodecane-tetra-acetic acid (Gd-DOTA) (abbreviated as LPS+Gd-DOTA) and their distribution in the inner ear after
either intratympanic or intracochlear administration.
Results: Measurements of relaxivities (r1 and r2) showed that LPS+Gd-DOTA had efficient visible signal
characteristics for MRI. In vivo studies demonstrated that LPS+Gd-DOTA with 130 nm size were efficiently taken up
by the inner ear at 3 h after transtympanic injection and disappeared after 24 h. With intracochlear injection,
LPS+Gd-DOTA were visualized to distribute throughout the inner ear, including the cochlea and vestibule with fast
dynamics depending on the status of the perilymph circulation.
Conclusion: Novel LPS+Gd-DOTA were visible by MRI in the inner ear in vivo demonstrating transport from the
middle ear to the inner ear and with dynamics that correlated to the status of the perilymph circulation.
Background
Treatments of inner ear diseases with traditional strate-
gies have had limited success and the goal of sensory
organ and nerve repair or regeneration has yet to be
achieved. One of the greatest challenges has been the
limitations to passage through the blood-inner ear bar-
riers and uncontrollable delivery of treatment agents
after either intravenous or oral administration (Figure 1)
[1]. Multifunctional nanoparticles (MFNPs) are a promis-
ing new means for the delivery of gene or drug to the
inner ear for the treatment of inner ear diseases including
sensorineural hearing loss (SNHL) and Meniere’s disease.
Eight types of MFNPs are currently under development
within the European Union consortium, Nanoear [2]
with the intention that they can be applied with an intra-
tympanic, minimally-invasive approach in the clinic.
MFNPs can be functionalized with the application of sur-
face ligands to improve cellular or nuclear internalization
to improve the targeted delivery of therapeutic agent. In
some of our preliminary studies lipid nanocapsules were
shown using confocal microscopy to become distributed
in different cochlear cell populations and liposome nano-
particles functionalized with TrkB ligand were interna-
lized into cochlear cells after round window membrane
permeation [3,4].
In the process of optimizing the functionalization of
each type of nanoparticle, it is essential to be able to
trace their passage through the cochlea. However, it is
problematic to track the MFNPs in the inner ear by his-
tological means. First, the appearance of autofluores-
cence from lipofuscin granules, which are found in the
cochleae of humans, chinchillas, guinea pigs and rats,
impairs the detection of the fluorescence signals from
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the MFNP targets [5-10]. Second, the inner ear is com-
posed of fluids, soft tissue, and bone [1] (Figure 1). This
results in signal loss in histological study, which is
incapable of retaining the inner ear fluids. Finally, it is
inconvenient to observe the dynamics of MFNPs in the
inner ear in histological studies.
MRI is an excellent tool to trace MFNPs that are
labeled with a contrast agent through the inner ear by
detecting their signal changes in both the inner ear
fluids and soft tissue in vivo. The critical regions of the
cochlea, including the lateral wall, spiral ganglion cells,
and cochlear nerve, are also demonstrated with the
resolution of a 4.7 T MRI [11,12]. Gadolinium- tetra-
azacyclo-dodecane-tetra-acetic acid (Gd-DOTA) was
shown to be efficiently taken up into rat inner ears and
detected at 60 min post-transtympanic injection with
greater signal intensity seen in the scala vestibuli than in
the scala tympani and no uptake into the endolymph
after four hours [11]. In the present study, amphiphilic
MRI-traceable liposome nanoparticles were first devel-
oped from 1,2-ditetradecanoyl-sn-glycero-3-phos-
phoethanolamine-N-diethylenetriaminepentaacetic acid
(gadolinium salt) [DMPE-DTPA (Gd)] (LPS-DTPA-Gd).
The contribution of effective Gd (water accessible Gd)
to MR signal was evaluated by disassembling Gd chelate
lipid nanoparticles with 5% sodium dodecyl sulfate
(SDS). Finally, effective MRI traceable liposome nano-
particles were developed by encapsulating Gd-DOTA in
the nanoparticles. These nanoparticles, which are abbre-
viated LPS+Gd-DOTA, were finally visualized in vivo in
the rat inner ears with MRI.
Results
Contribution of effective Gd to MR signal intensity of
LPS-DTPA-Gd
In phantom testing, LPS-DTPA-Gd showed characteris-
tics of a T1-contrast agent, but the maximum available
concentration of the nanoparticles was unable to induce
enough signal intensity for in vivo application. Nanopar-
ticles dissociated by 5% SDS demonstrated T1 and T2
relaxation times similar to that of Gd-DOTA with the
same molar concentration of Gd (Table 1). As the ratio
of Gd chelate to lipid within the material was already
maximized, an alternative strategy was pursued to
enhance the r1 of the nanoparticles. LPS+Gd-DOTA
nanoparticles were developed by encapsulating Gd-
DOTA into the aqueous core of liposomes to obtain
nanoparticles better visible by MR imaging. T1 relaxa-
tion time of purified LPS+Gd-DOTA at 160 folds dilu-
tion was close to that of LPS-DTPA-Gd at 1 mM
concentration while T1 relaxation time of unpurified
LPS+Gd-DOTA at 320 folds dilution was still signifi-
cantly shorter than both of them (Table 1). Unpurified
LPS+Gd-DOTA in artifical perilymph showed r1 of
2.2 S-1mM-1 and r2 of 4.4 S-1mM-1 while the purified
LPS+Gd-DOTA generated r1 of 0.033 S-1mM-1 and r2 of
0.037 S-1mM-1 in both artifical perilymph and HEPES.
Transportation of LPS+Gd-DOTA through the middle-
inner ear barriers
When applied to the middle ear cavity through trans-
tympanic injection, 1 mM LPS+Gd-DOTA nanoparticles
containing 500 mM Gd-DOTA were detected in the
middle ear cavity with strong T1-weighted signal which
decayed between 3 h to 6 h post administration (Figure
2 and Figure 3). In the inner ear, LPS+Gd-DOTA
Figure 1 Illustration of rat inner ear anatomy and
transportation routes of substances to be gained in the inner
ear after different administrations. After intratympanic delivery,
agents may enter the inner ear through the round window
membrane (1) and annular ligament (2), which surrounds the stapes
footplate within the oval window and comprises the
stapediovestibular joint (3). Stapedial artery (4) is a prominant
structure in the rat middle ear, which runs through the obturator
foramen of the stapes and inferior to the round window niche. The
inner ear is composed of the cochlea (5) and vestibule. The
vestibule contains three semicircular canals including the lateral (6),
posterior (7) and superior canals (8), and the saccule (9) and utricle
(10). The crista (11), which is located in each ampulla, is the sensory
structure of the semicircular canals. The macula (12) is the sensory
structure of both the saccule and utricle. The cochlea contains three
chambers, which are the scala tympani (13), the scala vestibuli (14),
and the scala media (15). The scala tympani and vestibuli are filled
by perilymph (high sodium-containing fluid). The scala media is
filled with endolymph (high potassium-containing fluid) and also
contains the sensory structure, the organ of Corti (16). The basilar
membrane (17), which extends from the osseous spiral lamina (18),
separates the scala media from scala tympani. Reissner’s membrane
(19) separates the scala media from scala vestibuli. Spiral ganglion
cells (20), which are located in the modiolus, send peripheral
processes to the hair cells and central processes to the cochlear
nuclei via cochlear nerve. Capillaries in the modiolus (21) and spiral
ligament (22) contribute to the blood-perilymph barrier, which is
the transportation pathway of agents to reach the inner ear after
intravenous or oral administration. Capillaries in the stria vascularis
(23) are attributable to the blood-endolymph barrier.
Zou et al. Journal of Nanobiotechnology 2010, 8:32
http://www.jnanobiotechnology.com/content/8/1/32
Page 2 of 11
nanoparticles were efficiently detected in the perilymph
at 3 h post-administration, which reached 21.1% (aver-
age of the vestibule, scala vestibuli, and scala tympani)
of that in the middle ear cavity (Figure 2 and Figure 3).
After 6 h, the singal intensity in the inner ear slightly
increased though statistic significance was not achieved
indicating that more LPS+Gd-DOTA nanoparticles were
gained in the inner ear. 3D rendering image showed
that abundant nanoparticles retained in the vestibule
and perilymphatic compartments of the basal lower turn
(Figure 4). Within the cochlea, additional nanoparticles
had diffused into the higher turns of the cochlea, which
made the perilymph in the second turn and apex more
visible. The signal intensity in the brainstem was also
slightly enhanced at 6 h in comparison to 3 h though
without statistic significance (Figure 2 and Figure 3). An
important phenomenon was noticed, in that the uptake
of purified LPS+Gd-DOTA in the inner ear was influ-
enced by the posture of the animal after transtympanic
injection. In order to be able to scan immediately fol-
lowing injection, two rats were placed into the MRI
machine in the prone position and LPS+Gd-DOTA
nanoparticles were not detected in their inner ears at 3
hours post-administration. However, when rats were
laid in the lateral position with the exposed ear upwards
for about 2.5 h before scanning, obvious uptake of LPS
+Gd-DOTA occurred in the inner ear at 3 h post-
administration (Figure 2). LPS+Gd-DOTA nanoparticles
were not detectable in the inner ear after neither 24 h
nor 48 h in either group. Unpurified LPS+Gd-DOTA
nanoparticles were efficiently detected in the perilymph
of the inner ear at 40 min post-transtympanic injection
(Figure 5).
When Gd-DOTA (100 mM) alone was injected into
the middle ear cavity, universal distribution in the inner
ear was observed within 1 h (Figure 6). When same
regions of interest were quantified, transport efficacy of
Gd-DOTA across the middle-inner ear barriers into the
inner ear compartments was significantly higher than
that of LPS+Gd-DOTA at 3 h post-administration (p <
0.01, student t-test) (Figure 7).
Distribution of LPS+Gd-DOTA in the inner ear after
intracochlear injection
Intracochlear administration of LPS+Gd-DOTA with a
volume 5 μl (1 mM LPS+Gd-DOTA containing 500
mM Gd-DOTA) in a closed perilymph circulation sys-
tem through a catheter failed to produce visible signal
in the inner ear. 10 μl volume of the same LPS+Gd-
DOTA induced bright signal on T1-weighted images
mainly in the region adjacent to the injection, that is, in
the basal turn of the scala tympani, scala vestibuli, and
Table 1 Relaxation times of different liposome nanoparticles at certain concentrations
Samples Nanoparticle
Concentrations
Gd
concentrations
Relaxation times (mS)
(mean ± SD)
T1 T2
LPS-DTPA-Gd 1 mM 0.5 mM 1897 ± 370 273 ± 4
LPS-DTPA-Gd+5%SDS 1 mM 0.5 mM 1697 ± 380 455 ± 5
Gd-DOTA 0.5 mM 1566 ± 324 447 ± 5
pLPS+Gd-DOTA* 0.00625 mM 3.125 mM 1980 ± 11 620 ± 7
upLPS+Gd-DOTA† 0.003125 mM 1.5625 mM 184 ± 13 102 ± 1
*purified LPS+Gd-DOTA, samples were diluted 160 folds; † unpurified LPS+Gd-DOTA, samples were diluted 320 folds.
Figure 2 Visualization of LPS+Gd-DOTA in the middle ear cavity and inner ear of rat after transtympanic injection using T1-weighted
2D MRI. LPS+Gd-DOTA nanoparticles (1.0 mM LPS+Gd-DOTA containing 500 mM Gd-DOTA) were delivered to the left middle ear. At 3 h time
point (A-C), they were detected in the middle ear cavity, vestibule, and cochlea. Aftert 6 h (D-F), these regions with uptake of nanoparticles
showed brighter signal and the second turn and apex of the cochlea became more visible. 1st: the basal turn; 2nd: the second turn; BS:
brainstem; L: left ear; ME: middle ear; R: right ear; ST: scala tympani; SV: scala vestibuli; Vest: vestibule. Particle sizes = 150 ± 20 nm. Scale bar = 1
mm.
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Figure 3 Semi-quantification of LPS+Gd-DOTA in the middle
ear cavity and inner ear of rat after transtympanic injection
demonstrated by T1-weighted 2D MRI. 1.0 mM LPS+Gd-DOTA
(containing 500 mM Gd-DOTA) was administered. At 3 h post-
administration, LPS+Gd-DOTA nanoparticles were efficiently
detected in the perilymph, which reached 21.1% (average of the
vestibule, scala vestibuli, and scala tympani) of that in the middle
ear cavity. LPS+Gd-DOTA intensity decreased in the middle ear cavity
while increased in the inner ear and brainstem form 3 h to 6 h after
intra tympanic administration. The region of interest was shown in
the images. BS: brainstem; ME: middle ear; ST: scala tympani; SV: scala
vestibuli; Vest: vestibule.
Figure 4 3D rendering of T1-weighted MRI demonstrating
spatial distribution of LPS+Gd-DOTA in the rat inner ear after
transtympanic injection. 1.0 mM LPS+Gd-DOTA (containing 500
mM Gd-DOTA) was administered. Abundant nanoparticles retained
in the vestibule (Vest) and perilymphatic compartments of the basal
lower turn. SCC: semicircular canal; ST: scala tympani; SV: scala
vestibuli.
Figure 5 Different uptake of unpurified and purified LPS+Gd-
DOTA in rat inner ear after transtympanic injection shown by
MPR single view of T1-weighted 3D MR imaging. Unpurified LPS
+Gd-DOTA were efficiently taken up in the inner ear at 40 min after
transtympanic injection at a concentration of 1 mM (containing 500
mM Gd-DOTA) (A and B). The signal intensity of purified LPS+Gd-
DOTA (B and C) in the inner ear was significantly lower than that of
unpurified LPS+Gd-DOTA judged by vision. LW: lateral wall; Mod:
modiolus; MPR: multiplanar reconstruction; SM: scala media; ST: scala
tympani; SV: scala vestibuli; Vest: vestibule; SCCs: semicircular canals;
unpur: unpurified LPS+Gd-DOTA; pur: purified LPS+Gd-DOTA.
Particle sizes = 300 ± 20 nm. Sacle bar = 500 μm.
Figure 6 MPR single view of T1-weighted 3D MR imaging of
the rat inner ear after transtympanic injection of Gd-DOTA. Gd-
DOTA distributed universally in the cochlea and vestibule at 3 h
post-transtympanic injection. LW: lateral wall; Mod: modiolus; MPR:
multiplanar reconstruction; SCCs: semicircular canals; SM: scala
media; ST: scala tympani; SV: scala vestibuli; Vest: vestibule. Scale bar
= 1 mm.
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modiolus immediately after intracochlear injection, (Fig-
ure 8). However, no further diffusion to the distal loca-
tions of the inner ear was visualized with prolonged
observation time. When 50 μl was injected, using higher
pressure to drive the nanoparticles, a broader distribu-
tion of LPS+Gd-DOTA in the inner ear was visualized,
including the cochlea and the adjacent scala vestibuli.
An abundance of LPS+Gd-DOTA nanoparticles were
demonstrated in the modiolus at the level of the basal
turn. In the scala vestibuli, the signal intensity was
lower than in the scala tympani (Figure 8). At 56 min,
LPS+Gd-DOTA nanoparticles diffused to distal sites,
such as the apex of the cochlea and the semicircular
canals in the vestibular organ (Figure 8).
Intracochlear administration of LPS+Gd-DOTA nano-
particles through gelatin sponge applied to an open
perilymph system, with windows created in both the
scala vestibuli and scala tympani, induced highly intense
bright signal in the inner ear on T1-weighted images
acquired at 30 min (Figure 9). At this time point, the
signal intensity in the perilymph of the vestibule was
higher than in the perilymph of the cochlea, which was
Figure 7 Semi-quantitative comparison of signal ratios in the
perilymphatic compartments over the middle ear cavity
between LPS+Gd-DOTA and Gd-DOTA acquired by T1-
weighted 2D MRI. LPS+Gd-DOTA was transported less effectively
than Gd-DOTA alone through the middle-inner ear barriers (**p <
0.01, student t-test). ME: middle ear; ST: scala tympani; SV: scala
vestibuli; Vest: vestibule.
Figure 8 Dynamic distribution of LPS+Gd-DOTA in the inner ear after intracochlear delivery in closed perilymphatic compartments
demonstrated by MPR single view of T1-weighted 3D MRI. 1 mM nanoparticles containing 500 mM Gd-DOTA were administered. In the
cochlea, LPSG+Gd-DOTA filled SM at the beginning, but were cleaned from SM after 56 m (A, B, and C). In the vestibule, LPS+Gd-DOTA retained
in the proximal locations of SCCs, but distributed to the distal parts of SCCs at 56 m post-injection (D, E, F). 1st: the basal turn; 2nd:the second
turn; 4 m, 12 m, and 56 m: 4 minutes, 12 minutes, and 56 minutes; Mod: modiolus; MPR: multiplanar reconstruction; SSCs: semicircular canals;
SM: the scala media; SM-h1st: SM of the higher basal turn; SM-h2nd: SM of the higher second turn; ST: the scala tympani; SV: the scala vestibuli;
Vest: vestibule. Scale bar = 500 μm.
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in turn higher than the modiolus. Homogeneous distri-
bution of LPS+Gd-DOTA nanoparticles was observed
throughout the perilymphatic compartments of the
cochlea. A dynamic reduction of signal in the hook
region of the scala tympani and the modiolus of the
cochlea was demonstrated, which became faint at
120 min post-administration (Figure 9). In the vestibular
organ, gradual enhancement occurred in the semicircu-
lar canals over 120 min while no visible change was
found in the vestibule, which remained bright through-
out this period (Figure 9).
Discussion
In the present work, we demonstrated that multifunc-
tional liposome nanoparticles, which were tagged with
gadolinium, were visualized by MRI. T1 signal enhance-
ment correlates to the amount of water accessible to the
gadolinium, shown by the phenomenon that SDS treat-
ment induced T1 relaxation time of LPS-DTPA-Gd
equivalent to that of Gd-DOTA at the same concentra-
tion. It was reported that Gd-DOTA and Gd-DTPA
showed similar relaxivities [13]. This suggested that
each LPS-DTPA-Gd molecule became water accessible
upon dissolution by SDS. Because the ratio of Gd to
lipid is nonadjustable in LPS-DTPA-Gd, there was diffi-
culty in generating sufficient MR signal. Alternatively,
encapsulation of Gd-DOTA into the liposomes was an
improved technique to increase the amount of gadoli-
nium available for MR imaging. With this method it
was possible to encapsulate 500 mM Gd into the lipo-
somes compared to LPS-DTPA-Gd where the maximum
concentration of incorporated Gd was 0.5 mM.
Moreover, highly monodisperse NPs were obtained
when Gd-DOTA was encapsulated into the liposomes.
This is critical for quality control in pharmaceutics, and
correlates with treatment efficacy. It is important to
note that the gadolinium within LPS+Gd-DOTA nano-
particles is carried in the aqueous core and the shell can
be manufactured to be identical to that of the treatment
nanoparticles. Therefore, this MRI study is directly
translatable for predicting the destination of these lipo-
some nanoparticles in clinical use to carry genes or
drugs.
Gd-DOTA-tagged liposome nanoparticles were
demonstrated within the inner ears of rats in vivo using
MRI. After intracochlear injection, nanoparticles dif-
fused throughout the inner ear efficiently and immedi-
ately reached the modiolus, which includes the spiral
Figure 9 Dynamic distribution of LPS+Gd-DOTA in the inner ear after intracochlear delivery in an open perilymphatic compartments
demonstrated by MPR single view of T1-weighted 3D MRI. 1 mM nanoparticle containing 500 mM Gd-DOTA were administered.
Intracochlear dynamics was shown in A through D; intravestabular dynamics was shown in E through H. From 30 min to 120 min post-
administration of LPS+Gd-DOTA, signal intensities decayed gradually in the STL1, STH1, and Mod; but retained stable in the SVL1, SVH1, and Vest.
30 m, 50 m, etc.: 30 minutes etc; Mod: modilous; MPR: multiplanar reconstruction; SSCs: semicircular canals; STH1: scala tympani of the higher
basal turn; STL1: scala tympani of the lower basal turn; SVH1: scala vestibuli of the higher basal turn; SVL1: scala vestibuli of the lower basal turn;
Vest: vestibule.
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ganglion cells. Therefore, the multifunctional liposome
nanoparticle is a promising vector to deliver treatment
agents to inner ear targets from a cochlear implant,
where the spiral ganglion cells are a major concern.
After intracochlear injection, distribution of nanoparti-
cles in distal destinations, such as the semicircular
canals, within one hour indicated that liposome nano-
particle can also be applied in drug delivery to the ves-
tibular organ. The efficacy of delivery was enhanced by
injecting a larger volume, likely due to the increased
driving force, or by opening a second window into the
scala vestibuli to avoid the pulsatile egress of cerebrosp-
inal fluid (CSF) from the scala tympani. This reduced
distribution with lower injection volumes suggests that
diffusion of the hydrophobic liposome nanoparticles in
the hydrophilic perilymph may be problematic. In the
clinic practice of cochlear implantation, the constant
release of nanoparticles from an advanced drug delivery
electrode could resolve this diffusion issue.
Application of therapy into the middle ear, as a mini-
mally invasive technique for inner ear drug delivery, is a
favorable approach for the treatment of inner ear diseases
that are not suitable for cochlear implantation. The out-
come of intratympanic treatment would depend in a
large part upon the efficacy of transportation from the
middle ear to the inner ear. The existence of at least two
pathways, including the round window membrane and
the oval window, from the rat middle ear to the inner ear
were recently supported by an in vivo MRI study [11].
There are a number of additional studies concerning
round window membrane passage in the literature. The
round window membrane appears well adapted for active
transport. There are microvilli on the surface of outer
epithelium and abundant organelles, such as mitochon-
dria, rough endoplasmic reticulum, and a well-developed
Golgi complex, that provide metabolic support and
mechanisms for transport activity [14]. Our own unpub-
lished data showed the appearance of clathrin in the
round window membrane of rats, which suggests a speci-
fic pinocytosis. There is discontinuity in the basement
membrane of the inner epithelium and loose junctions
between inner epithelial cells that provide potential open-
ings to support diffusion.. Both the surface characteristics
and the size of the nanoparticles are important factors
that affect the passage from the middle ear to the inner
ear. One μm latex microspheres were reported to pass
through the round window membranes of chinchillas
and Rhesus monkeys [15]. In that study, the quantity of
latex microspheres that passed through the round win-
dow membrane was unknown, but this is an important
factor to define in studies of therapy directed toward
inner ear diseases. In the present observations, liposome
Gd nanoparticles of 130 nm passed the middle ear-peri-
lymph barriers in quantities sufficient for MR imaging in
3 h and reached a signal intensity of above 1/5 of that in
the middle ear cavity. Our preliminary histological study
demonstrated augmented distribution of LPS+Gd-DOTA
into the utricle of the vestibule than that in the spiral
ligament capillary and spiral ganglion cells of the cochlea
at 8 h following transtympanic injection of TRITC
labeled LPS+Gd-DOTA in specimens taken from the rat
after MRI study (data not shown). This implies the invol-
vement of oval window in transporting LPS+Gd-DOTA.
The oval window pathway was proved by abolish of
immediate Gd-DOTA uptake in the vestibule and scala
vestibuli induced by oval window sealing (data not
shown). Potential uptake of TRITC labeled LPS+Gd-
DOTA in other organs such as the brain, liver, and kid-
ney should be investigated in a future study. These same
advanced MFNPs showed targetability of their distribu-
tion in rat cochleae when functionalized with TrkB ligand
[4] after intratympanic administration.
Conclusions
In the present study, novel MRI visible multifunctional
liposome nanoparticles were designed by encapsulating
Gd-DOTA inside the hydrophilic core of the nanoparti-
cles. Acceptable r1 values were realized in the final pro-
ducts. The Gd-DOTA-tagged liposome nanoparticles
were visualized in the rat inner ear in vivo after both
intracochlear and transtympanic injections. The intraco-
chlear approach induced stronger signals on T1-
weighted images. MRI also proved to be an excellent
tool to monitor the purity of the Gd-DOTA-tagged lipo-
some nanoparticles. There are potentially broad applica-
tions for these novel types of nanoparticles in future
biomedical investigations.
Methods
Reagents and animals
Sphingosine (Sph), egg phosphatidylcholine (EggPC), and
1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol)-2000] (ammonium salt)
[DSPE-PEG2000], 1,2-ditetradecanoyl-sn-glycero-3-phos-
phoethanolamine-N-diethylenetriaminepentaacetic acid
(gadolinium salt) [DMPE-DTPA (Gd)], were from Avanti
polar lipids (Alabaster, AL). Gd-DOTA (DOTAREM) was
from Guerbet, Cedex, France. Hepes, and EDTA, were
from Sigma. The purity of lipids was checked by thin-layer
chromatography on silicic acid coated plate (Merck,
Darmstadt, Germany) developed with a chloroform/
methanol/water mixture (65:25:4, v/v/v). Examination of
the plates after iodine staining, and when appropriate,
upon UV illumination revealed no impurities. Lipid con-
centrations were determined gravimetrically with a high
precision electrobalance (Cahn, Cerritos, CA). The other
chemicals were of analytical grade and from standard
sources.
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Twenty-six male Wister rats, weighing between 270 g
and 440 g, were provided by the Experimental MRI
Laboratory, Department of Neurology, Helsinki Univer-
sity Central Hospital, FIN-00029 HUS, Helsinki, Finland.
All animal experiments were approved by the Ethical
Committee of the University of Tampere (permission:
LSLH-2006-4143/Ym23). Animal care and experimental
procedures were conducted in accordance with Eur-
opean legislation. Animals were divided into 3 groups:
transtympanic injection of LPS+Gd-DOTA (TTI), intra-
cochlear administration of LPS+Gd-DOTA with open
perilymph circulation (IC-OPC), and intracochlear
administration of LPS+Gd-DOTA with close perilymph
circulation (IC-PPC) (Table 2). In TTI group, 2 rats
received injection of unpurified LPS+Gd-DOTA and 12
rats were injected purified LPS+Gd-DOTA. All experi-
mental procedures were performed under general anaes-
thesia, induced by intraperitoneal injections of
medetomidine hydrochloride (0.5 mg/kg, Domitor,
Orion, Finland) and ketamine (75 mg/kg, Ketalar, Pfizer,
UK) and maintained at half dosage of the agents with
the animal’s eyes protected by Viscotears® (Novartis
healthcare A/S, Danmark).
Preparation of liposomes containing Gd-DTPA-DMPE
(LPS-DTPA-Gd)
Appropriate lipids along with DMPE-DTPA (Gd) (Gd che-
late lipid) were mixed and solvent was evaporated under
nitrogen to obtain a thin lipid film which was subsequently
dried overnight under nitrogen. Lipid film was hydrated
with buffer and resulting MLV’s were then sequentially
extruded 400 (five times), 200 (five times), and 100 nm
(seven times) polycarbonate Millipore filters to yield unila-
mellar liposomes containing gadolinium in both leaflets
(Figure 10A). The size of LPS-DTPA-Gd was 130 ± 20 nm.
Preparation of liposomes encapsulating Gd-DOTA
(LPS+Gd-DOTA)
Lipids were dissolved in chloroform and subsequently
mixed in this solvent so as to obtain the desired compo-
sitions. The solvent was removed using a gentle stream
of nitrogen whereafter the dry lipid residues were main-
tained under reduced pressure for at least 24 h to
remove trace amounts of chloroform. The lipid film was
hydrated with Gd-DOTA solution (500 mM, Guerbet,
Cedex, France) at 60°C for 60 min. The resulting lipid
suspensions were extruded (Avestin, Ottawa, Canada)
through 400 (five times), 200 (five times), and 100 nm
(seven times) polycarbonate Millipore filters to yield
large unilamellar vesicles (LUV’s) containing Gd-DOTA
both inside as well as outside of the liposomes (Figure
10B). After extrusion, external gadolinium was removed
by Sephadex G-50 (fine) quick spin columns (Roche
Diagnostics GmbH, Mannheim, Germany). Before and
after removal of the external Gd-DOTA average particle
size (Zav, using DLS, Zetasizer Nano ZS, Malvern Instru-
ments Ltd., UK) of 300 ± 20 and 130 ± 20 nm was
obtained (Figure 11). All LPS+Gd-DOTA nanoparticles
contain 500 mM Gd-DOTA. Liposomes containing Gd-
DOTA were stable even after one week of preparation
as confirmed by DLS, revealing no changes in Zav.
Table 2 Grouping of animals and time of MRI
measurement post-LPS+Gd-DOTA administration
Groups N* MRI time post-LPS+Gd-DOTA administration
TTI
Unpurified 2 40 min, 90 min
purified 12 40 min, 90 min, 3 h, 6 h, 24 h, 48 h
IC-OPC 6 1 h
IC-CPC 5 0 min, 20 min, 30 min, 40 min, 1 h
*One positive control animal receiving transtympanic injection of Gd-DOTA
(100 mM) was not counted in the numbers. IC-OPC: intracochlear
administration with open perilymph circulation; IC-CPC: intracochlear
administration with closed perilymph circulation; TTI: transtympanic injection.
Figure 10 Schematic representation of liposomes containing
gadolinium chelate lipid (LPS-DTPA-Gd) (and liposomes
encapsulating Gd-DOTA (LPS+Gd-DOTA). A: LPS-DTPA-Gd; B: LPS
+Gd-DOTA.
Figure 11 Size distribution by intensity of purified liposomes
(total lipid concentration 1 mM) containing DTPA-Gd (LPS-
DTPA-Gd) or encapsulating Gd-DOTA (LPS+Gd-DOTA) obtained
by dynamic light scattering. Temperature was maintained at 25°C.
LPS-DTPA-Gd (A) showed more dispersed size distribution than LPS
+Gd-DOTA (B).
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Phantom study
A 4.7 T MR scanner with bore diameter of 155 mm
(PharmaScan, Bruker BioSpin, Germany) was used in
both phantom and in vivo MR measurements. The max-
imum gradient strength was 300 mT/m with an 80-μs
rise time. A dedicated rodent head coil (linear bird cage
coil) with diameter of 38 mm was used for the phantom
and animal studies. To evaluate T1 and T2 relaxation
times of LPS-DTPA-Gd nanoparticles and analyze the
contribution of water-accessible Gd-DTPA to MR signal,
the nanoparticle solutions were prepared with physiolo-
gical saline at a concentration of (1 mM containing
0.5 mM Gd). 5% SDS was applied to disassemble the
nanoparticles and expose all the lipid-bond Gd-DTPA
to the water. This was done to detect MRI signal from
all of the Gd-DTPA associated with the nanoparticles,
including that amount within the nanoparticles that
could be shielded by the lipid from proton interaction.
Gd-DOTA diluted with physiological saline at a concen-
tration of 0.5 mM was used as a positive control. Plastic
phantom tubes (400 μl, AgnTho’s AB, Sweden) were
filled with the solutions of Gd-DOTA, LPS-DTPA-Gd
nanoparticles, or LPS-DTPA-Gd nanoparticles plus 5%
SDS.
In order to measure relaxivities, r1 and r2, of LPS
+Gd-DOTA, solutions of various concentrations were
placed into plastic phantom tubes arranged concentri-
cally within a 50 ml syringe. Dilutions were made with
artificial perilymph containing 145.5 mM NaCl, 2.7 mM
KCl, 2.0 mM MgSO4, 1.2 mM CaCl2, 5.0 mM HEPES,
pH adjusted to 7.4 [16]. Negative controls were prepared
using either plain artificial perilymph or HEPES buffer.
Each sample was prepared in duplicate.
T2 relaxation time was determined using a multi-slice
multi-echo sequence (MSME), based on CPMG (Carr-
Purcell Meiboom-Gill) spin echo (SE) [repetition time
(TR) 1500 ms, echo time (TE) 7-229 ms, 32 echo times,
matrix size 128 × 128, single slice, slice thickness
2.0 mm, field of view (FOV) 5.0 cm, resolution 0.098 ×
0.130 mm2, number of excitation (NEX) 3]. T1 relaxa-
tion times were determined by rapid acquisition with
relaxation enhancement (RARE) sequence with variable
TR (TR 100, 432, 859, 1458, 2472, 7500 ms, TEeff
8.7 ms, RARE factor 2, NEX 1, matrix size 128 × 128,
FOV 5 cm, single slice with slice thickness 2.0 mm).
Transtympanic injection of LPS+Gd-DOTA
LPS+Gd-DOTA nanoparticles were administered
through transtympanic injection under an operating
microscope as previously reported [11]. An incision of
approximately 1 mm length was made in the anterior
superior quadrant of the tympanic membrane by a 25
gauge needle to release any potential air bubble. Either
purified or unpurified 0.04 ml LPS+Gd-DOTA (1 mM
LPS+Gd-DOTA containing 500 mM Gd-DOTA) were
injected into the middle ear cavity through the posterior
superior quadrant of the tympanic membrane. As a
positive control, Gd-DOTA (100 mM) was transtympa-
nically injected as above.
Intracochlear administration of LPS+Gd-DOTA to open
perilymphatic compartments
The bulla was exposed through a post-auricular
approach. Working under the operating microscope, a
hole was drilled through the bulla with a 2 mm dia-
meter burr. The round window membrane was identi-
fied superior to the stapedial artery as reported
previously [1]. The scala tympani of the basal turn was
opened with a 0.5 mm cutting burr inferior to the stape-
dial artery and the round window. A second opening
was made in the scala vestibuli of the basal turn. After
wicking away the perilymph that egressed through the
opening, two pieces of gelatin sponge soaked in LPS
+Gd-DOTA (the size of each piece was proximately
3 mm3 after soaking in the LPS+Gd-DOTA solution)
were placed against the openings in the middle ear cav-
ity. The bulla opening was covered by muscle and the
wound was sutured closed.
Intracochlear injection of LPS+Gd-DOTA into closed
perilympatic compartments
After drilling into the scala tympani of the basal turn as
above, polyimide tubing (MicroLumen Inc., Tampa,
USA) was inserted intraluminally into a polyethylene
tubing (I.D. 0.28 mm, O.D. 0.61 mm, Becton Dickinson,
Franklin Lakes, USA) and fixed with nail polish. The
tubing was filled with LPS+Gd-DOTA solution. After
opening the scala tympani of the basal turn with a
0.5 mm cutting burr, the high performance polyimide
tubing tip (MicroLumen, Tampa, USA), which was con-
nected to polyethylene tubing (I.D. 0.28 mm, O.D.
0.61 mm, Becton Dickinson and Company, USA) and
primed with LPS+Gd-DOTA solution was inserted into
the scala tympani and was sealed circumferentially with
Histoacryl (enbucrilate) glue (Aesculap AG, Tuttlingen,
Germany). LPS+Gd-DOTA nanoparticles were initially
applied by bolus injection of 5 μl, but they failed to
demonstrated any MRI detectable signal for uncertain
reasons. Although it is a physiologically excessive
volume, 50 μl was injected and produced satisfying MR
signal. The remaining observations were performed with
50 μl LPS+Gd-DOTA. The bulla opening was covered
by muscle and the wound was sutured closed.
In vivo MRI observation of LPS+Gd-DOTA in the inner ear
The body temperatures of the rats were maintained by
circulating warm water and their respirations were
recorded with Physio Tool-1.0.b.2 program (Bruker,
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Germany). Rats were placed in the magnet with the ears
positioned at the isocenter. 2D and 3D MRI measure-
ment was performed. T1-weighted 2D images were
acquired with RARE sequence (TR/TEeff 500/10 ms,
RARE factor 4, matrix size 256 × 192, slice thickness 0.5
mm, FOV 2.5 × 2.5 cm2, resolution 0.098 × 0.13 mm2,
NEX 33). T1-weighted 3D images were acquired with
RARE sequence (TR/TEeff 500/12 ms, RARE factor 16,
matrix size 64 × 64 × 64, FOV 0.89 × 0.89 × 0.89 cm3,
resolution 0.139 × 0.139 × 0.139 mm3, NEX 2).
For the groups who had either intracochlear adminis-
tration of LPS+Gd-DOTA with open perilymph circula-
tion or transtympanic injection of LPS+Gd-DOTA, MRI
scanning commenced immediately after the procedure.
After setting up the geometry with T2-weighted 2D
imaging, T1-weighted 2D, and T1-weighted 3D images
were acquired at different time points. In the group of
intracochlear injection of LPS+Gd-DOTA with closed
perilymph circulation, LPS+Gd-DOTA nanoparticles
were injected after setting up the MRI geometry. Then
T1-weighted 2D, and T1-weighted 3D images were
acquired as above. MRI measurements were followed up
to 48 h in the group of transtympanic injection of LPS
+Gd-DOTA and for one hour in the group of intraco-
chlear administration of LPS+Gd-DOTA with open peri-
lymph circulation (Table 2).
3D volume rendering of the inner ear MRI
OsiriX v3.3.2 (OsiriX Foundation, Geneva, Switzerland)
software was applied for 3D rendering of the 3D raw
stacked MR images of the inner ear. 3D volume render-
ings were created for visualisation of the inner ear struc-
tures with the ability to rotate the images into various
orientations and to create photographs.
Quantification of signal intensity and statistics
ParaVision PV 4.0 (Bruker, Germany) software was
used for post-processing of MR images and calcula-
tions of T1 and T2 relaxation times in phantom and
signal intensity measurements in the inner ear com-
partments. Signal intensities in the region of interest
were measured in the middle ear cavity, the vestibule,
the scala vestibuli and scala tympani in the higher
basal turn, and the brainstem using ParaVision 4.0.
Differences in the signal intensities between 3 h and
6 h time points among these compartments were com-
pared with student t-test. Signal intensity ratio of the
vestibule, the scala vestibuli, and scala tympani over
the middle ear was defined as the indicator of trans-
port efficacy and compared between LPS+Gd-DOTA
and Gd-DOTA groups with student t-test. A difference
was considered to be statistically significant at P <
0.05. Photoshop CS3 software was used for labeling
and demonstration of the inner ear anatomy in MR
image.
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